- Home
- CHRS vs BCV Comparison
CHRS vs BCV Comparison
Compare CHRS & BCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- BCV
- Stock Information
- Founded
- CHRS 2010
- BCV 1971
- Country
- CHRS United States
- BCV United States
- Employees
- CHRS 177
- BCV N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- BCV Finance/Investors Services
- Sector
- CHRS Health Care
- BCV Finance
- Exchange
- CHRS Nasdaq
- BCV Nasdaq
- Market Cap
- CHRS 149.9M
- BCV 115.1M
- IPO Year
- CHRS 2014
- BCV N/A
- Fundamental
- Price
- CHRS $1.37
- BCV $20.98
- Analyst Decision
- CHRS Strong Buy
- BCV
- Analyst Count
- CHRS 4
- BCV 0
- Target Price
- CHRS $4.51
- BCV N/A
- AVG Volume (30 Days)
- CHRS 1.4M
- BCV 26.3K
- Earning Date
- CHRS 11-05-2025
- BCV 01-01-0001
- Dividend Yield
- CHRS N/A
- BCV 8.13%
- EPS Growth
- CHRS N/A
- BCV N/A
- EPS
- CHRS 1.55
- BCV N/A
- Revenue
- CHRS $272,209,000.00
- BCV N/A
- Revenue This Year
- CHRS N/A
- BCV N/A
- Revenue Next Year
- CHRS $126.00
- BCV N/A
- P/E Ratio
- CHRS $0.88
- BCV N/A
- Revenue Growth
- CHRS 52.33
- BCV N/A
- 52 Week Low
- CHRS $0.66
- BCV $14.09
- 52 Week High
- CHRS $2.43
- BCV $18.11
- Technical
- Relative Strength Index (RSI)
- CHRS 73.83
- BCV 67.66
- Support Level
- CHRS $1.26
- BCV $20.76
- Resistance Level
- CHRS $1.39
- BCV $21.20
- Average True Range (ATR)
- CHRS 0.08
- BCV 0.26
- MACD
- CHRS 0.02
- BCV 0.02
- Stochastic Oscillator
- CHRS 94.10
- BCV 82.40
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.